All In Biotech

Drug Trial Radar · NCT04837170

Safety and Efficacy Evaluation of S (+) - Ketamine in Adults

Safety and Efficacy Evaluation of S(+)-Ketamine for Postoperative Acute Pain in Adults in Perioperative Settings: A Multicenter, Randomized, Open-label, Active Controlled Pragmatic Clinical Trial

Last checked: Nov 19, 2026Latest source record: Apr 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 12,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

12,000

Planned (sponsor's estimate)

Start

May 1, 2021

Primary completion

Jun 1, 2022

Study completion Jun 30, 2022

Sponsor

Lead sponsor
Chinese PLA General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jiangsu Provincial People's Hospital; Beijing Hospital; The Affiliated Hospital of Qingdao University; Renmin Hospital of Wuhan University; First Affiliated Hospital Xi'an Jiaotong University; First Affiliated Hospital, Sun Yat-Sen University; Shengjing Hospital; Southern Medical University, China
First posted
Apr 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, open-label, active controlled pragmatic clinical trial that evaluates the safety and efficacy of S (+) -ketamine for postoperative acute pain in adults in perioperative settings.

Conditions

  • Postoperative Pain
  • Adults
  • Anesthesia

Interventions

  • Conventional therapy + S (+)-KetamineDrug

    Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction,maintenance or postoperative analgesia.

  • Conventional therapyDrug

    Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The area under the broken line of NRS scoreTime frame: Hour 0-48 after surgery
  2. Opioid consumptionTime frame: Hour 0-48 after surgery

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.